Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments Corp. (NASDAQ: CLOV) combines Medicare Advantage coverage with AI-driven healthcare solutions through its proprietary Clover Assistant platform. This centralized news hub provides investors and healthcare professionals with essential updates on CLOV's operational milestones, technology developments, and regulatory progress.
Access real-time updates including earnings reports, partnership announcements, and Medicare Advantage plan expansions. Our curated collection features official press releases about Clover Assistant enhancements, Counterpart Health deployments, and value-based care initiatives. Track coverage of key financial metrics, membership growth, and technology licensing agreements.
Stay informed about CLOV's progress in chronic disease management solutions and health equity programs. The resource serves both active traders monitoring short-term developments and long-term investors analyzing strategic direction. All content is verified through primary sources including SEC filings and corporate communications.
Bookmark this page for streamlined access to CLOV's latest corporate announcements and market-moving updates. Combine these timely reports with fundamental analysis tools for comprehensive investment research.
Clover Health (CLOV) announced it will report its Q1 2021 financial results on May 17, 2021, prior to market open. A conference call will be held at 8:30 a.m. ET to discuss the results. The company's mission is to enhance health outcomes for seniors using a technology platform that analyzes health data, aiming to improve medical outcomes and reduce costs. Clover has offices in multiple locations, including Nashville and San Francisco.
Clover Health Investments, Corp. (Nasdaq: CLOV) announced the appointment of Demetrios L. Kouzakas to its Board of Directors, where he will also serve on the Audit Committee. Kouzakas brings extensive experience from his previous roles in the Medicare division at UnitedHealth and as Director of the Center for Medicare at CMS. CEO Vivek Garipalli highlighted Kouzakas's expertise in Medicare regulations and strategic business acumen as vital for Clover's mission to improve health outcomes for seniors. Kouzakas expressed excitement about Clover's technology fostering better care coordination.
Clover Health Investments, Corp. (Nasdaq: CLOV) announced the appointment of William “Bill” Robinson to its Board of Directors as the Chair of the Talent & Compensation Committee. Robinson brings extensive experience, including serving as CHRO for Sabre and Coventry Health Care, and has a strong background in HR leadership at General Electric. CEO Vivek Garipalli highlighted Robinson's proven track record as a significant asset for Clover's mission to enhance health outcomes for seniors across America. Clover Health utilizes technology to improve clinical outcomes and reduce patient costs.
Clover Health has launched a new health and wellbeing magazine, Clover Living, aimed at individuals aged 60 and above. The quarterly publication will provide health education and advice, focusing on chronic disease management, and will be distributed to Clover Health members, doctors, and the general public. With oversight from a medical editorial board, the magazine aims to enhance Clover's outreach and engage the Medicare population, ultimately improving health outcomes. The first issue is set to be released in late Spring 2021.
Clover Health Investments, Corp. (Nasdaq: CLOV) announced participation in a five-year clinical study funded by the National Institutes of Health (NIH) alongside major institutions like Massachusetts General Hospital and Harvard Medical School. The study aims to evaluate the effectiveness of video-based decision aids in improving advance care planning for patients with severe chronic illnesses receiving home-based care. It will involve 500 patients and assess impacts on medical preferences, hospice utilization, and healthcare costs.
Clover Health (Nasdaq: CLOV) will present at the Barclays Global Healthcare Conference on March 10, 2021, at 10:55 a.m. Eastern Time. The presentation will be available via a live webcast on Clover Health's investor website. Clover Health focuses on using technology to enhance healthcare outcomes for seniors.
Clover Health reported a 46% year-over-year increase in total revenue, reaching $673 million in 2020. The company saw a growth in its membership, surpassing 58,000 members, while the lives managed by its Clover Assistant increased by 43% to 32,400. Despite these gains, Clover posted a net loss of $(91.6) million. For 2021, Clover anticipates revenues between $820 million and $850 million, as well as expansion in Medicare Advantage membership. The company aims to implement its Direct Contracting program to further enhance growth.
Clover Health (Nasdaq: CLOV) announces its first edition of "Clover Assistant Online" on March 2, 2021, at 10:00 a.m. PT. President & CTO Andrew Toy and the clinician team will showcase key features of the Clover Assistant platform, incorporating physician feedback and planned enhancements. The event will be accessible as a pre-recorded webcast in the investor relations section of Clover Health's website. Clover Health aims to improve health outcomes and reduce costs for seniors through its innovative technology.
Clover Health (Nasdaq: CLOV) will release its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. The company aims to enhance health outcomes for seniors through its innovative technology platform. A conference call will follow at 5:00 p.m. ET to discuss results in detail. Investors can participate by dialing (833) 693-0547 or accessing a live webcast via the company’s investor relations website. These results will provide insights into the company's performance and strategic direction.
The law firm Federman & Sherwood has launched an investigation into Clover Health Investments, Corp (CLOV) regarding possible violations of federal securities laws. This follows a February 4, 2021 report by Hindenburg Research, which alleged that Clover's business practices and its software, Clover Assistant, are under investigation by the Department of Justice for various issues, including kickbacks and undisclosed deals. Following the report, CLOV shares dropped by $1.72, closing at $12.23.
FAQ
What is the current stock price of Clover Health Investments (CLOV)?
What is the market cap of Clover Health Investments (CLOV)?
